Corticotropin-releasing factor 1 receptor antagonists: a patent review

Bibliography

• Vale WW, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-7
   PubMed Web of Science ®Google Scholar
• Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing factor receptor. Proc Natl Acad Sci USA 1993;90:8967-71
   PubMed Web of Science ®Google Scholar
• Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92:836-40
   PubMed Web of Science ®Google Scholar
• Donaldson C J, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endrocrinology 1996;137:2167-70
   PubMedGoogle Scholar
• Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001;98:2843-8
   PubMed Web of Science ®Google Scholar
• Lewis K, Perrin MH, Blount A, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001;98:7570-5
   PubMed Web of Science ®Google Scholar
• Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010;15:371-83
   PubMed Web of Science ®Google Scholar
• Gilligan PJ. Corticotropin-releasing factor receptor antagonists. Expert Opin Ther Patents 2006;16:913-24
   PubMed Web of Science ®Google Scholar
• Dzierba CD, Hartz RA, Bronson JJ. Recent advances in corticotropin-releasing factor receptor antagonists. Annu Rep Med Chem 2008;43:3-19
   Google Scholar
• Nova Pharmaceutical Corp. Corticotropin-releasing factor antagonism compounds. US5063245; 1991
   Google Scholar
• Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-81
   PubMed Web of Science ®Google Scholar
• Ising M, Zimmerman US, Kunzel HE, et al. High-affinity CRF (1) receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007;32:1941-9
   PubMed Web of Science ®Google Scholar
• Binneman B, Feltner D, Kolluri S, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Pyschiatry 2008;165:617-20
   PubMed Web of Science ®Google Scholar
• Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder. Neurocrine Biosciences press release 2010. Available from: www.neurocrine.com [Last accessed 22 February 2013]
   Google Scholar
• Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010;27:417-25
   PubMed Web of Science ®Google Scholar
• Evaluation of GSK561679 in Women with Post-Traumatic Stress Disorder. Clincaltrials.gov identifier NCT01018992. Available from: clinicaltrials.gov [Last accessed 22 February 2013]
   Google Scholar
• Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women with High Anxiety. Clincaltrials.gov identifier NCT01187511. Available from: clinicaltrials.gov [Last accessed 22 February 2013]
   Google Scholar
• Pexacerfont for Stress-induced Food Craving. Clincaltrials.gov identifier NCT01656577. Available from: clinicaltrials.gov [Last accessed 22 February 2013]
   Google Scholar
• Pexacerfont to Reduce Stress-induced Tobacco Craving. Clinicaltrials.gov identifier NCT01557556. Available from: clinicaltrials.gov [Last accessed 22 February 2013]
   Google Scholar
• Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics. Clinicaltrials.gov identifier NCT01227980. Available from: clinicaltrials.gov [Last accessed 22 February 2013]
   Google Scholar
• Keller PA, Bowman M, Dang KH, et al. Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. J Med Chem 1999;42:2351-7
   PubMed Web of Science ®Google Scholar
• Gross RS, Guo Z, Dyck B, et al. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists. J Med Chem 2005;48:5780-93
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical Co. 8-Aryl-4-alkylpyrollo[2,3,4-de]quinolin-5(4H)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives. WO2009008552; 2009
   Google Scholar
• Pfizer Ltd. Substituted 6,6-heterobicyclic derivatives. WO9808846; 1998
   Google Scholar
• Emory University. Compounds, compositions, methods of synthesis, and methods of treatment. WO2010096426; 2010
   Google Scholar
• Pfizer Ltd. Preparation of substituted purine compounds as CRF1 receptor antagonists. WO2009144632; 2009
   Google Scholar
• Miller DC, Klute W, Brown AD. Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles. Bioorg Med Chem Lett 2011;21:6108-11
   PubMedGoogle Scholar
• Fleck BA, Hoare SRJ, Pick RR, et al. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 2012;341:518-31
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Co. Thiazolylpyrazolopyrimidines as CRF1 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008036579; 2008
   Google Scholar
• Eli Lilly and Co. Preparation of thiophene pyrazolopyrimidine compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists. WO2008036541; 2008
   Google Scholar
• SB Pharmaco Puerto Rico, Inc. Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto. WO2006044821; 2006
   Google Scholar
• Eli Lilly and Co. Imidazopyridazine compounds. WO2006102194; 2006
   Google Scholar
• Eli Lilly and Co. Imidazopyridazine compounds. WO2006107784; 2006
   Google Scholar
• Gehlert DR, Cippitelli A, Thorsell A, et al. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridizine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 2007;27:2718-26
   PubMed Web of Science ®Google Scholar
• Du Pont Pharmaceuticals Co. Nitrogen substituted imidazo[4,5-c]pyrazoles as corticotropin releasing hormone antagonists. WO9910350; 1999
   Google Scholar
• Eisai R&D Management Co. Pyrazoloxazole compound. WO2011043387; 2011
   Google Scholar
• Novartis AG. Pyrazolo[5,1-b]oxazole derivatives as CRF1 antagonists. WO2010015628; 2010
   Google Scholar
• Novartis AG. Pyrazolo[5,1-b]oxazole derivatives as CRF-1 receptor antagonists. WO2011092290; 2011
   Google Scholar
• Eisai R&D Management Co. Pyrazolothiazole compound. WO2011043381; 2011
   Google Scholar
• Eisai R&D Management Co. 3-Phenylpyrazolo[5,1-b]thiazole compounds. US20090259049; 2009
   Google Scholar
• Takahashi Y, Hashizume M, Shin K, et al. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists. J Med Chem 2012;55:8450-63
   PubMedGoogle Scholar
• Bristol-Myers Squibb Co. Pyrazinone modulator of corticotropin-releasing factor receptor activity. WO2010014280; 2010
   Google Scholar
• Du Pont Merck Pharmaceutical Co. Pyrazinones and triazinones and their derivatives thereof. WO9811075; 1998
   Google Scholar
• Hartz RA, Ahuja VT, Zhuo X, et al. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. J Med Chem 2009;52:7653-68
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity. WO2010014687; 2010
   Google Scholar
• Whitten JP, Xie YF, Erickson PE, et al. Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists. J Med Chem 1996;39:4354-7
   PubMed Web of Science ®Google Scholar
• Saito T, Obitsu T, Kondo T, et al. 6-7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists. Bioorg Med Chem 2011;19:5432-45
   PubMedGoogle Scholar
• Saito T, Obitsu T, Minamoto C, et al. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists. Bioorg Med Chem 2011;19:5955-66
   PubMed Web of Science ®Google Scholar
• Tanabe Seiyaku Co. Pyrazolopyrimidine derivative. WO2006126718; 2006
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Tricyclic compounds and use thereof. US20090186879; 2009
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Fused heterocyclic compounds. WO2006116412; 2006
   Google Scholar
• Takeda K, Terauchi T, Shin K, et al. Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists. Bioorg Med Chem Lett 2012;22:4756-61
   PubMedGoogle Scholar
• Takeda Pharmaceutical Co. Ltd. Benzimidazole compounds. WO2008051533; 2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Fused heterocyclic compounds having CRF antagonistic activity. WO2008082003; 2008
   Google Scholar
• Elf Sanofi. Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them. US5464847; 1995
   Google Scholar
• A trial evaluating the efficacy and tolerability of SSR125543 in outpatients with major depressive disorder (AGATE). Clincaltrials.gov identifier NCT01034995 Available from: clinicaltrials.gov [Last accessed 22 February 2013]
   Google Scholar
• Yoon T, De Lombaert S, Brodbeck R, et al. 2-Arylpyrimidines: novel CRF1 receptor antagonists. Bioorg Med Chem Lett 2008;18:4486-90
   PubMedGoogle Scholar
• Ono Pharmaceutical Co. Bicyclic heterocyclic compound. WO2007069565; 2007
   Google Scholar
• Ono Pharmaceutical Co. Bicyclic heterocyclic compound. WO2007069671; 2007
   Google Scholar
• Ono Pharmaceutical Co. Bicyclic heterocyclic compound. WO2008136377; 2008
   Google Scholar
• Takeda K, Teruachi T, Hashizume M, et al. Design, synthesis and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF1 receptor antagonists. Bioorg Med Chem Lett 2012;22:5372-8
   PubMedGoogle Scholar
• Neurogen Corp. CRF1 Receptor ligands comprising fused bicyclic heteroaryl moieties. WO2008083070; 2008
   Google Scholar
• Saito T, Obitsu T, Kohno H, et al. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazine-(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists. Bioorg Med Chem 2012;20:1122-38
   PubMedGoogle Scholar
• Neurogen Corp. N-Benzimidazolylmethyl-and N-indolylmethy-benzamides and their use as CRF modulators. WO2000059888; 2000
   Google Scholar
• Japan Tobacco. Benzamide derivative and use thereof. WO2001062718; 2001
   Google Scholar
• Wilson DM, Termin AP, Mao L, et al. Arylamidrazones as novel corticotropin releasing factor receptor antagonists. J Med Chem 2002;45:2123-6
   PubMedGoogle Scholar
• Molteni V, Penzotti J, Wilson DM, et al. N-Phenylphenylglycines as novel corticotropin releasing factor receptor antagonists. J Med Chem 2004;47:2426-9
   PubMedGoogle Scholar
• Saito K, Kasai T, Nagura Y, et al. Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distension in rats. Gastroenterology 2005;129:1533-43
   PubMed Web of Science ®Google Scholar
• Novartis AG. Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists. WO2010015655; 2010
   Google Scholar
• Novartis AG. Cyclohexyl amide derivatives as CRF receptor antagonists. WO2011092293; 2011
   Google Scholar
• Novartis AG. Cyclohexyl amide derivatives as CRF receptor antagonists. WO2011095450; 2011
   Google Scholar
• Paez-Pareda M, Hausch F, Holsboer F. Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin Investig Drugs 2011;20:519-35
   PubMedGoogle Scholar
• Koob G, Zorrilla EP. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology 2012;37:308-9
   PubMed Web of Science ®Google Scholar
• Hoare SRJ. Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today 2005;10:417-27
   PubMed Web of Science ®Google Scholar
• Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000;24:410-14
   PubMed Web of Science ®Google Scholar
• Preil J, Muller MB, Gesing A, et al. Regulation of the hypothalamic – pituitary – adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology 2001;142:4946-55
   PubMedGoogle Scholar
• Chandler DJ. Something's got to give: psychiatric disease on the rise and novel drug development on the decline. Drug Discov Today 2013;18:202-6
   PubMed Web of Science ®Google Scholar